Analyst Gil Blum from Needham maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report) and keeping the price target at $10.00.
Gil Blum’s rating is based on several positive developments for Autolus Therapeutics. The company is making significant progress with the launch of Aucatzyl (obe-cel) in relapsed/refractory acute lymphoblastic leukemia (r/r ALL), having activated 33 sites and secured reimbursement for over 85% of U.S. lives. This progress is expected to continue with plans to activate more sites, aiming for a total of 60.
Additionally, the upcoming R&D Day on April 23rd is anticipated to be a key event, where initial data for systemic lupus erythematosus (SLE) will be shared, alongside development strategies in autoimmune diseases (AID). The ongoing MAA review in the EU and U.K. with potential approvals in the second half of 2025 further supports the positive outlook. The company’s strong financial position, ending the year with $588 million, including a milestone payment, also contributes to the Buy rating.
Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Geron, and Cartesian Therapeutics. According to TipRanks, Blum has an average return of -11.7% and a 30.29% success rate on recommended stocks.
Questions or Comments about the article? Write to editor@tipranks.com